Document Detail

Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
MedLine Citation:
PMID:  22510009     Owner:  NLM     Status:  MEDLINE    
PURPOSE/AIM: To explore changes in morphology and function in the rabbit retina after intravitreal high-dose injection of three commonly used VEGF inhibitors.
MATERIALS AND METHODS: Forty-eight rabbits of mixed strain (6 months of age, body weight ≈ 3 kg) were randomized into four groups (n = 12). They were examined with full-field electroretinography (ERG) and with multifocal electroretinography (mf ERG) prior to drug exposure. The rabbits were then injected intravitreally with bevacizumab, ranibizumab, pegaptanib, or with a balanced saline solution. The dose of VEGF inhibitor was chosen to achieve a vitreous concentration approximately three times higher than the one clinically used in the adult human eye. ERG was then performed 8 weeks postinjection, and mf ERG 9 weeks postinjection. After 9 weeks, the rabbits were sacrificed and the sectioned retina was studied. Immunohistochemical analysis was performed of rods, cones, rod bipolar cells, horizontal cells, and amacrine cells.
RESULTS: Rabbits injected with VEGF inhibitors all showed significantly lower amplitude of the dark-adapted b-wave rod-mediated response to dim light, compared to the rabbits injected with BSS. The a wave (reflecting photoreceptor function) in the response to single flash white light was however not affected. Immunohistochemistry revealed a significant reduction in PKC labeling of rod bipolar cells in pegaptanib and ranibizumab injected eyes whereas bevacizumab injected eyes displayed normal PKC labeling. No apparent morphological change was seen with markers for remaining retinal cells.
CONCLUSIONS: Our results indicate that the use of high-dose intravitreal VEGF inhibitors in the rabbit eye affects rod-mediated retinal function and PKC expression in rod bipolars cells for at least 9 weeks after drug administration. The three VEGF inhibitors influence the retina slightly differently. These results are important for the understanding of drug action and when devising therapeutical strategies in new areas such as retinopathy of prematurity where vitreous volume is significantly lower compared to the adult eye.
Anna Cardiakidis Myers; Monica Lövestam Adrian; Anitha Bruun; Fredrik Ghosh; Sten Andréasson; Vesna Ponjavic
Related Documents :
20819669 - Vision, subjective accommodation and lens mobility after tetraflex accommodative intrao...
3407719 - Imbalanced adaptation of accommodation and vergence produces opposite extremes of the a...
22557989 - Reduced neurobehavioral impairment from sleep deprivation in older adults: contribution...
7320379 - A retinoscopic method of assessing accommodative performance of young human infants.
11069179 - An area for vergence eye movement in primate frontal cortex.
17081859 - Magnetic resonance imaging of aging, accommodating, phakic, and pseudophakic ciliary mu...
11849749 - Phase advance of sleep and temperature circadian rhythms in the middle years of life in...
11489579 - Lens epithelial cell regeneration of a capsule-like structure during postoperative heal...
7977569 - Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current eye research     Volume:  37     ISSN:  1460-2202     ISO Abbreviation:  Curr. Eye Res.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-18     Completed Date:  2012-07-16     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8104312     Medline TA:  Curr Eye Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  399-407     Citation Subset:  IM    
Department of Ophthalmology, Lund University, Lund, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Aptamers, Nucleotide / administration & dosage*
Disease Models, Animal
Intravitreal Injections
Macular Degeneration / drug therapy,  pathology,  physiopathology
Retina / drug effects,  pathology*,  physiopathology*
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Changes in anterior chamber parameters with the pentacam rotating scheimpflug and axial length measu...
Next Document:  Effect of Curcumin on miRNA Expression in Human Y79 Retinoblastoma Cells.